Code : 9345-352844      Created Date : Sunday, May 28, 2017   Visit : 1571

Digestive Disease Week by Dr. Rasoul Sotoudehmanesh

Digestive Disease Week by Dr. Rasoul Sotoudehmanesh
Application Code :
306-0116-0066
 
Created Date : Saturday, May 14, 2016-07:18 07:18:04Update Date : Monday, March 13, 2017-09:22 09:22:00
IP Address : 194.225.213.75Submit Date : Monday, March 13, 2017-09:22 09:22:30Email :r.sotoudehmanesh@gmail.com
Personal Information
Name : Rasoul
Surname : Sotoudehmanesh
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : Professor
Tel : +98-21-22143056
Information of Congress
Title of the Congress : Digestive Disease Week
Title of your Abstract : Non-Inferiority of Pharmacologic Prophylaxis vs. Pancreatic Duct Stenting for Prevention of Post-ERCP Pancreatitis - An Interim Report
Destination Country : United States
From : Saturday, May 21, 2016
To : Tuesday, May 24, 2016
Abstract(Please copy/paste the abstract send to the congress) : Background/aims: Acute pancreatitis is the most feared adverse event of endoscopic retrograde cholangiopancreatography (ERCP). The aim of this study is to assess the non-inferiority of a combination of pharmacological measures as compared to pancreatic duct stenting (PDS) for the prevention of post-ERCP pancreatitis (PEP).
Patients and methods: Patients at high risk for PEP received a combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate. They were randomized to pharmacological prophylaxis alone (group A) or pharmacological prophylaxis + PDS (Group B). Serum amylase levels and clinically pertinent measurements were performed in all patients after ERCP. The sample size was calculated to be 400 subjects.
Results: At the time of this writing 190 patients were enrolled. 94 received pharmacological prophylaxis alone and 96 pharmacological prophylaxis + PDS. Twenty-seven patients developed pancreatitis: 14 (14.9%) in group A and 13 (13.8%) in group B (p=0.84). Severe acute pancreatitis occurred in one patient in group A (1.1%) and two patients in group B (2.1%). A statistically significant difference was not observed in mean serum amylase levels after 24 hours between the two groups (336 ± 586 vs. 304 ± 448.6, U/L, p=0.67). There were no adverse events related to the prophylactic measures used in either group.
Conclusions: The combination of rectal indomethacin, sublingual nitrate and hydration appears to effectively reduce the risk of PEP. The addition of PDS offers no significant added value.
Keywords of your Abstract : Pancreatitis, ERCP, PD stent
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/30250/Forms/306/Acceptance_3.pdf
The presentation : Oral
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/30250/Forms/306/Cover _1.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/30250/Forms/306/Published Abs_1.pdf
Where has your abstract been indexed? : ISI
If you choose other, please name : Gastoenterology Journal
The Congress Reporting Form
How many volunteers were present at the Congress? : more than 2000 people
Delegates from which countries presented in the congress? : USA, Canada, different countries from Europe and Asia, Africa
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : UEGW
What were the responses to your talking points? Were specific questions or concerns raised? : The audiences enjoyed because of novelty of the study and also very strict for eligibility, inclusion and exclusion criteria. Some of them had some comments and asking some questions. One of the good comments was the reason for high rate of acute pancreatitis n both pharmacologic and endoscopic (PD stent) intervention groups. Actually it was due to the number of risk factors for developing post-ERCP pancreatitis in both groups. At the same time our study has been done in a tertiary governmental fellow-based hospital and in this field the rate of pancreatitis can be higher. Also they asked me regarding the rate of post-ERCP pancreatitis and the size of PD stents used in the study. One of question was about the complications of PD stenting.
If you met staff members, please list their full names & positions. : Dr. B.J.Elmunzer, Dr. Alan Barkun, Dr. Anand Sahaei
Please inform us if there are any follow up actions we need to talk with the members of the congress : you can ask concerning the importance of our study, do promotion for the attendings who have novelty in their projects and also as they have a role for increasing the scientific knowledge. You may have more protection and support the academic staff for this type of activities which could be a honor for the university and our dear country. The studies with oral presentations have a good credit for our university. You can offer to the congress for more attention to the universities with good projects as an index for rankings of universities.
Your experiences about the travel processes(Providing ticket, accommodation,...) : I provided booking ticket and hotel by myself
Please give a briefing of your own observations and outcomes of the congress: : Very useful and scientific congress better than European ones. At the same time during four days you can find lectures in 20 halls in different filed of gastroenterology and hepatology. Usually the first two days were about post-graduate course that is a very good review for general and common gastrointestinal and hepatobiliary disorders. Some sessions was related to best of Video presentation and it was a very practical point of view. The other portion of this congress was the active participation in exhibition halls where the companies both accessory and endoscopy producers presented their products. We could know new cncepts and ideas regarding the accessories and new endosops. We also met the members and bosses of these companies and I as the director of advanced endosopy education program talked about our problem for post-marketings of their products after sanction removal.

 

Your Comments :
captcha
Close